5-((1H-1,2,4-Triazol-1-yl)methyl)-3-bromo-2-(difluoromethoxy)pyridine → 2-Methoxy-3-(1H-pyrazol-4-yl)-5-(1H-1,2,4-triazol-1-ylmethyl)pyridine
Reaktionsgleichung
[N:1]1([CH2:6][C:7]2[CH:8]=[C:9](Br)[C:10]([O:13][CH:14](F)F)=[N:11][CH:12]=2)[CH:5]=[N:4][CH:3]=[N:2]1.[NH:18]1[CH:22]=[CH:21][C:20](B(O)O)=[N:19]1>>[CH3:14][O:13][C:10]1[C:9]([C:21]2[CH:22]=[N:18][NH:19][CH:20]=2)=[CH:8][C:7]([CH2:6][N:1]2[CH:5]=[N:4][CH:3]=[N:2]2)=[CH:12][N:11]=1Komponenten
3
Versuchsvorschrift
The title compound was prepared in a manner analogous to Example 4, from Intermediate 13 and the appropriate pyrazole boronic acid. 1H NMR (400 MHz, DMSO-d6) δ 8.69 (s, 1H), 8.07 (s, 1H), 8.01 (q, J=2.3 Hz, 2H), 7.99 (s, 1H), 5.37 (s, 1H), 3.94 (s, 3H), 2.52 (s, 1H). [M+H]=257.26.
Quellen und Nachweise
- ORD-Eintrag
- ord-c628c4ff4bce4677881739d3f89f5239
- Quelldatensatz
- uspto-grants-2015_09
- DOI